DeepMed Research

MedImmune LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1987-01-01

Employees: 5K

Market Cap: -

Website: http://medimmune.com

Clinical Trials

A Study to Evaluate the Immunogenicity of Quadrivalent Live Attenuated Influenza Vaccine (LAIV) in Children

Phase 3

Completed

Conditions: Healthy or Stable Chronic Illness

Interventions: Biological: Q/LAIV (MEDI3250)
Biological: FluMist/B/Yamagata
Biological: FluMist/B/Victoria

First Posted Date: 2010-03-23

Last Posted Date: 2011-09-26

Lead Sponsor: MedImmune LLC

Target Recruit Count: 2312

Registration Number: NCT01091246

Locations: 🇺🇸
Research Site, Franklin, Wisconsin, United States

A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Biological: Mavrilimumab 50 mg
Other: Placebo
Biological: Mavrilimumab 10 mg
Biological: Mavrilimumab 30 mg
Biological: Mavrilimumab 100 mg

First Posted Date: 2010-01-18

Last Posted Date: 2018-06-25

Lead Sponsor: MedImmune LLC

Target Recruit Count: 516

Registration Number: NCT01050998

Locations: 🇺🇦
Research Site, Kyiv, Ukraine

Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL)

Phase 1

Completed

Conditions: Chronic Lymphocytic Leukemia
Non-Hodgkin Lymphoma

Interventions: Drug: CAT-8015 50 mcg/kg
Drug: CAT-8015 20 mcg/kg
Drug: CAT-8015 40 mcg/kg
Drug: CAT-8015 30 mcg/kg
Drug: CAT-8015 60 mcg/kg

First Posted Date: 2009-12-11

Last Posted Date: 2018-04-09

Lead Sponsor: MedImmune LLC

Target Recruit Count: 23

Registration Number: NCT01030536

Locations: 🇵🇱
Research Site, Łódź, Poland

An Observational Study to Assess Respiratory Syncytial Virus (RSV) Respiratory Events Among Premature Infants

Completed

Conditions: Healthy

First Posted Date: 2009-09-24

Last Posted Date: 2012-11-14

Lead Sponsor: MedImmune LLC

Target Recruit Count: 3000

Registration Number: NCT00983606

Locations: 🇺🇸
Research Site, Monroe, Wisconsin, United States

A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies

Phase 1

Completed

Conditions: B-cell Malignancies
Cancer

Interventions: Drug: MEDI-551
Drug: Rituximab

First Posted Date: 2009-09-24

Last Posted Date: 2020-05-13

Lead Sponsor: MedImmune LLC

Target Recruit Count: 136

Registration Number: NCT00983619

Locations: 🇪🇸
Research Site, Madrid, Spain

A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or Myositis

Phase 2

Completed

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: Sifalimumab

First Posted Date: 2009-09-18

Last Posted Date: 2016-10-27

Lead Sponsor: MedImmune LLC

Target Recruit Count: 118

Registration Number: NCT00979654

Locations: 🇨🇱
Research Site, Santiago, Chile

A Study to Assess Pharmacokinetics, Safety and Tolerability of Multiple Doses of CAT-354 in Subjects With Moderate Asthma

Phase 1

Terminated

Conditions: Moderate Asthma

Interventions: Biological: CAT-354 1mg/kg
Biological: CAT-354 10mg/kg
Biological: CAT-354 5 mg/kg
Other: Placebo

First Posted Date: 2009-09-10

Last Posted Date: 2017-05-02

Lead Sponsor: MedImmune LLC

Target Recruit Count: 23

Registration Number: NCT00974675

Locations: 🇬🇧
Chiltern International Limited, Slough, Berkshire, United Kingdom

A Study to Evaluate the Effectiveness and Safety of MEDI-528 in Adults

Phase 2

Completed

Conditions: Asthma

Interventions: Biological: MEDI528 30 mg
Biological: MEDI528 100 mg
Biological: MEDI528 300 mg
Other: Placebo

First Posted Date: 2009-08-31

Last Posted Date: 2014-06-04

Lead Sponsor: MedImmune LLC

Target Recruit Count: 329

Registration Number: NCT00968669

Locations: 🇨🇳
Research Site, Taoyuan, Taiwan

A Study to Evaluate the Immunogenicity of Quadrivalent LAIV (MEDI8662) in Adults 18 to 49 Years of Age

Phase 3

Completed

Conditions: Healthy or Stable Underlying Chronic Medical Condition

Interventions: Biological: FluMist/B/Yamagata
Biological: FluMist/B/Victoria
Biological: Q/LAIV-BFS (MEDI8662)

First Posted Date: 2009-08-06

Last Posted Date: 2018-05-03

Lead Sponsor: MedImmune LLC

Target Recruit Count: 1800

Registration Number: NCT00952705

Locations: 🇺🇸
Coastal Clinical Research, Inc., Mobile, Alabama, United States
🇺🇸
Miami Research Associates, Miami, Florida, United States
🇺🇸
Benchmark Research, Metairie, Louisiana, United States

and more 13 locations

A Study of the Safety and Tolerability of MEDI-551 in Scleroderma

Phase 1

Completed

Conditions: Scleroderma

Interventions: Biological: MEDI-551
Other: Placebo

First Posted Date: 2009-07-27

Last Posted Date: 2014-11-13

Lead Sponsor: MedImmune LLC

Target Recruit Count: 50

Registration Number: NCT00946699

Locations: 🇬🇧
Research Site, London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy